89bio plans to invest up to $10m (€9m) in manufacturing and scale up, after raising $85m in an upsized IPO.
Teva launches Tarceva generic for the treatment of NSCLC, as it continues to expand its pipeline of oncology treatments.
The FDA approved Teva's generic for Sabril, the first generic for the drug, as the agency continues to focus its efforts to approve generics that face little competition.
Teva resolves generic patent infringement litigations that prohibited the manufacturing of two of its generic products.
Heavily indebted Teva says consolidating its global headquarters in Israel will generate “significant savings from a business and operations point of view”.
Teva is the latest firm to recall valsartan products after a probable carcinogen was detected in its supplier’s API.
A review of ‘disabling and potentially long-lasting side effects’ reported in relation to treatments of fluoroquinolone and quinolone prompted the PRAC recommendation.
The detection of cracks of the surface of glass vials has prompted a voluntary recall of Labetalol Hydrochloride Injection made at Pfizer’s troubled McPherson, Kansas facility.
Standard and Poor's says it is considering lowering Teva’s rating as Momenta Pharmaceuticals’s generic version of Copaxone closes in on launch.
The US FDA has upgraded the status of Pfizer’s McPherson manufacturing, hit with a warning letter last year.
Generic giant Teva is restructuring its organisation and leadership but says details of manufacturing changes will be announced next month.
Teva has lowered its 2017 guidance on the back of higher-than-expected generic price erosion and lower-than-expected Copaxone sales due to competition.
European regulators have approved a generic 40mg version of Teva Pharmaceutical Industries’ multiple sclerosis drug Copaxone (glatiramer acetate).
Teva Pharmaceutical Industries Ltd has confirmed its API plant in Netanya, Israel will close as part of the cost reduction programme announced last week.
Concerns about Pfizer’s fill/finish plant in McPherson, Kansas have prompted the US FDA to reject the firm’s biosimilar version of Amgen’s anaemia drug Epogen.
Particulate problems in sterile injectables and poor aseptic techniques landed Pfizer with a US FDA warning letter at a former Hospira facility in Kansas.
Momenta Pharmaceuticals has reiterated its belief that problems at a US Pfizer plant mean the FDA is unlikely to reach a decision on its 40mg version of Teva’s Copaxone before April.
Copaxone maker Teva Pharmaceutical Industries Ltd. saw higher active pharmaceutical ingredient (API) sales last year.
Teva has aggressively defended its market share for its blockbuster Copaxone says Momenta, six months after marketing partner Sandoz launched the first generic version in the US.
Sandoz has revealed it will close three manufacturing sites in Germany and India.
News from CPhI Japan
Generic drug use in Japan has started to increase but 'brand loyalty' is still a considerable challenge according to industry experts.
Teva must invest in its biomanufacturing network as the firm’s biologics aspirations grow beyond biosimilars, CEO Erez Vigodman told investors.
Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.
Teva says 5,000 jobs will be lost next year as it accelerates its global cost reduction programme, set to save $2bn (€1.48bn) annually by 2017.
French authorities are investigating if a packaging mix-up at generics giant Teva Pharmaceutical Industries played a role in the death of a man in Marseilles last week.
The US Environmental Protection Agency (EPA) says Teva still needs to address environmental issues at Missouri API plant landed with a $2.3m civil penalty.
Teva says the offloading of its Californian manufacturing facility is part of cost-cutting plans designed to save $2bn (€1.5bn). in the next few years.
The US FDA says Teva Pharmaceutical Industries’ plan to fix cGMP violations observed at its plant in Irving, California “lack sufficient corrective actions.”
Actavis to boost tablet capacity; and looking at Ratiopharm
Icelandic generics firm Actavis says expansion of its tablet plant will boost production capacity 50 per cent and create 50 new jobs.
Biologics boost for $2.7bn needle-free delivery market
Demand for new delivery options for biologic drugs will drive an expansion of the $2.7bn needle-free technology market over the medium-term, according to a new report by industry analysts Kalorama Information.
AZ to slash more European jobs and ramp-up China investment
AstraZeneca is to cut 1,400 jobs and close more manufacturing facilities by 2013, as it attempts to slim down in preparation for impending generic competition for some of its cornerstone drugs.
Pharmaceutical facility news in brief
in-PharmaTechnologist.com's periodic round-up of developments in
the field of pharmaceutical facilities includes news of two
environmental fines, MHRA plant approval and a strike at Teva.
Pliva seeks direction after lost royalties
Pliva, Eastern Europe's biggest drug maker by sales, saw its
profits take a massive dive in the first quarter of 2006, as a huge
loss of royalties could not be offset by the relatively small
growth in its generics business.
Actavis Group acquires Alpharma generics business
Actavis Group has announced the company has acquired the human
generics business of Alpharma, making the international generic
pharmaceuticals company one of the five largest companies in
generic pharmaceuticals worldwide in terms...
Sandoz eyeing Indian acquisition?
Sandoz, the generics subsidiary of Swiss pharmaceutical company
Novartis, is rumoured to be planning an acquisition in India in a
move that would give it back the top slot in the sector.
Teva to regain generics lead with Ivax purchase
Teva Pharmaceutical Industries continued its bid for world
domination in the generic pharmaceuticals sector yesterday with a
$7.4 billion cash and stock bid for US company Ivax, reports
Teva swings to profit in first quarter
Teva Pharmaceutical Industries' active pharmaceutical ingredients
(API) business is on track to become a $1 billion enterprise this
year, although growth in the first quarter of this year was almost
entirely from in-house sales,...
Teva reports sales surge in 2004
Israeli drug and active pharmaceutical ingredients (API) company
Teva has reported a sharp increase in sales in 2004, helped in part
by last year's $3.4bn (€2.6bn) acquisition of Sicor.
Teva snaps up Italian generics player
Israeli generics and active pharmaceutical ingredients (API)
company Teva Pharmaceutical Industries announced yet another
acquisition earlier today, this time for Pfizer's Italian generic
pharmaceutical marketing company Dorom.
Teva posts loss as Sicor buy bites, but sales soar
Isael's Teva Pharmaceutical Industries slipped into a loss in the
first quarter of 2004, as the cost of the acquisition of US
generics and active pharmaceutical ingredient (API) firm Sicor took
its toll, but for the first time...
Record year once again at Teva
Israel's Teva Pharmaceutical Industries has reported strong
increases in sales across its branded, generic and active
pharmaceutical ingredient (API) operations in the fourth quarter of
2003, as net income rose by more than a...
Teva takes Sicor to the altar
Israel's Teva plans to buy Sicor in a €2.9bn deal that will create
a powerhouse in generic pharmaceuticals and active pharmaceutical